发明名称 新規な融合タンパク質及びC型肝炎ワクチンの製造のためのその使用
摘要 <p>An immunogenic fusion protein includes at least, on the C-terminal side, a first peptide composed of the S protein deleted of the transmembrane domain thereof located at the N-terminal end thereof, of a hepatitis B virus (HBV) isolate, and on the N-terminal side, a second peptide composed of the transmembrane domain and of the ectodomain of at least one envelope protein of a hepatitis C virus (HCV) isolate. A hybrid nucleic acid molecule encoding the fusion protein, and a vector including the hybrid nucleic acid molecule, a subviral particle including the fusion protein, an immunogenic composition including at least the fusion protein, or at least the hybrid nucleic acid molecule, or at least the subviral particle, and a cell line for the production of the fusion protein, or of the hybrid nucleic acid molecule, or of the subviral particle are described.</p>
申请公布号 JP5656832(B2) 申请公布日期 2015.01.21
申请号 JP20110514100 申请日期 2009.06.16
申请人 发明人
分类号 C12N15/09;A61K31/7088;A61K35/76;A61K38/00;A61P1/16;A61P31/12;A61P31/14;C07K14/02;C07K14/18;C12N1/19;C12N5/10;C12N7/04 主分类号 C12N15/09
代理机构 代理人
主权项
地址